Biocon Biologics Partners with National Cancer Society of Malaysia to Launch Patient Assistance Program

Biocon Biologics Limited, a fully integrated global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Program (PAP) in Malaysia. The program aims to improve access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event.